Refine by
Coronary Arterial Articles & Analysis: Older
78 news found
For example, the Multiple Parts of Artery Tissue and Atherosclerosis Tissue Microarray, 30 Cases, 22 Cores (Catalog # CSCT001) consist of various sections of artery tissue and atherosclerosis tissue and can be used in IHC, ISH and other routine histology procedures. This tissue microarray includes various artery tissues ...
The publication presents results obtained from flow simulations in the coronary arteries of 25 patients with different degrees of stenoses and areas of occurrence. ...
The frequency of net-clinical benefit events - a composite of stroke or systemic embolism, major bleeding, myocardial infarction, acute coronary syndrome, or cardiovascular death - was 13.8 per 100 patient years in the rivaroxaban and 13.6 in the VKA group (95% CI 0.72 to 1.31, HR=0.97). ...
ByBayer AG
Food and Drug Administration (FDA) for XC001 as adjunctive therapy to coronary artery bypass grafting (CABG) in 2H21. The company also plans other clinical studies in additional cardiovascular indications, including heart failure caused by ischemic heart disease and as adjunctive therapy to percutaneous coronary intervention. ...
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular ...
MOTIV is a drug-eluting bioresorbable peripheral vascular scaffold made from REVA’s proprietary Tyrocore polymer that is designed to dissolve over time, leaving the artery free of a permanent implant and thereby allowing the artery to return to its natural movement or ...
CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the ...
Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ArterioSorb. ArterioSorb is an innovative ...
About the EXACT Study The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm trial. ...
Research showed that mtDNA heteroplasmy was 39.8% higher in patients with coronary artery disease than in control myocardial tissues. Meanwhile, research has also discovered an 87% increase in the total number of heteroplasmic mtDNA deletions in patients with coronary artery disease compared to the control group. ...
About PAD Cardiovascular diseases (CVD), including coronary artery disease (CAD) and peripheral artery disease (PAD), account for around 1 in every 3 deaths worldwide. ...
ByBayer AG
The Company’s products include MOTIV bioresorbable scaffolds for the treatment of peripheral artery disease, Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease, and TyroSphere embolic beads. ...
The simplicity of interpreting and displaying these results will increase patients’ understanding of their coronary artery disease. Jack Coats, CEO of CardioWise, Inc. said, “We are very pleased to partner with Lucem Health to bring SQuEEZ, our cardiac AI solution to the Lucem multi-modal data integration platform to bring novel insights to the point ...
The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United States. Dr. ...
The Shockwave C2 Coronary IVL Catheters, which are used for the treatment of coronary arterial calcification lesions, are approved in the United States, the European Union, and other select international jurisdictions, and have been used to help treat more than 70,000 patients globally who suffer from coronary ...
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today new data confirming excellent one-year outcomes with coronary IVL in both women and men. The one-year results from the Disrupt CAD clinical program were presented at the 2022 Scientific Sessions of the Society for ...
About the EXACT Study The Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (EXACT) clinical trial is a Phase 1/2 multicenter, open-label, single-arm trial. ...
VIDA is also announcing a new vascular biomarker: coronary artery calcium score (CACS) providing a cumulative Agatston score which is a measure of coronary artery calcification. ...
“As we continue to advance our robotic-assisted platform, the new facility will support our mission to elevate the standard of care and increase access to cutting-edge treatment for coronary artery and neurovascular disease.” The new facility marks the first of 15 new offices or major facility expansions that Siemens Healthineers plans in the U.S. ...
Based on the results of these studies, we have been using FFRangio as a standalone tool for physiologic assessment in patients undergoing coronary angiography, and it has become the standard of care in our cath lab replacing wire-based FFR. ...